Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761988 | 0.95 | GAA (0.61) | GAACYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL6716129 | 0.95 | GAA (0.61) | GAACYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL9333895 | 0.86 | GAA (0.47) | GAACYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL8537334 | 0.86 | LMNA (0.64) | GAACYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL98819 | 0.86 | GAA (0.52) | GAACYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL14557570 | 0.86 | GAA (0.52) | GAACYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL65969 | 0.86 | LMNA (0.64) | GAACYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL9015787 | 0.85 | L3MBTL1 (0.46) | GAACYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL27797742 | 0.83 | LMNA (0.60) | GAACYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL11328750 | 0.82 | L3MBTL1 (0.43) | GAACYP1A2CYP2C19L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802848-B2 | Melamine based mannich-compounds and a process for obtaining the same | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2014-08-12 | — | — | US | disclosed |
| US-20120277429-A1 | Melamine Based Mannich-Compounds and a Process for Obtaining the Same | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2012-11-01 | — | — | US | disclosed |
| US-8137452-B2 | Easy-to-clean, mechanically stable coating composition for metallic surfaces and process for coating a substrate using said composition | MASCO CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090181175-A1 | EASY-TO-CLEAN, MECHANICALLY STABLE COATING COMPOSITION FOR METALLIC SURFACES AND PROCESS FOR COATING A SUBSTRATE USING SAID COMPOSITION | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCUNG E.V. (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-1465578-A2 | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1461352-A2 | ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003053340-A2 | ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003040321-A2 | ANTISENSE MODULATION OF EIF2C1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003028637-A2 | ANTISENSE MODULATION OF SPHINGOSINE-1-PHOSPHATE LYASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003022227-A2 | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-0882720-B1 | METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2001-08-22 | — | — | EP | disclosed |
| US-6127538-A | HYDROXYALKYLATION OF A TRIAMINO TRIAZINE DERIVATIVE HAVING AT LEAST ONE REACTIVE NITROGEN BY REACTING WHILE HEATING WITH AN ALKANEDIOL OR ITS ADDUCT IN THE PRESENCE OF HYDROGEN AND A METAL CATALYST; BY-PRODUCT INHIBITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| EP-0882720-A1 | METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277429-A1 | Melamine Based Mannich-Compounds and a Process for Obtaining the Same | MAN2A1, MANBA, MAN2B2 | GAA 875/4885CYP1A2 332/4885CYP2C19 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.